Free tool
FAERS Monitor: Striverdi Respimat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203108 or its brand name (Striverdi Respimat, Olodaterol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
369
Serious
183
50% of reports
Hospitalization
95
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea54
- cough35
- off label use32
- drug ineffective30
- asthma14
- chest pain13
- chronic obstructive pulmonary disease13
- pneumonia13
- asthenia12
- chest discomfort11
- dizziness10
- palpitations10
- wheezing10
- death9
- fatigue9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2014 | 20 |
| 2015 | 56 |
| 2016 | 53 |
| 2017 | 47 |
| 2018 | 22 |
| 2019 | 29 |
| 2020 | 25 |
| 2021 | 29 |
| 2022 | 22 |
| 2023 | 22 |
| 2024 | 15 |
| 2025 | 15 |
| 2026 | 13 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,790 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic obstructive pulmonary diseaseSignal | 13 | 14.2 | 8.3 | 147 |
| wheezingSignal | 10 | 9.6 | 5.2 | 69 |
| coughSignal | 35 | 7.1 | 5.2 | 180 |
| asthmaSignal | 14 | 7.1 | 4.2 | 67 |
| chest discomfortSignal | 11 | 6.1 | 3.4 | 42 |
| dyspnoeaSignal | 54 | 5.4 | 4.2 | 196 |
| palpitationsSignal | 10 | 4.9 | 2.6 | 27 |
| chest painSignal | 13 | 4.0 | 2.3 | 27 |
| pneumoniaSignal | 13 | 2.3 | 1.3 | 8 |
| off label useSignal | 32 | 2.1 | 1.5 | 18 |
| asthenia | 12 | 1.8 | 1.0 | 4 |
| drug ineffective | 30 | 1.3 | 0.9 | 2 |
| dizziness | 10 | 1.1 | 0.6 | 0 |
| fatigue | 9 | 0.7 | 0.3 | 1 |
| death | 9 | 0.6 | 0.3 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.